Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors

Trial Profile

Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Tramadol (Primary) ; Amitriptyline
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors e-Therapeutics
  • Most Recent Events

    • 07 Apr 2016 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
    • 22 Mar 2016 According to an e-Therapeutics media release, the company announced results of the details analysis of this phase IIb trial.
    • 22 Mar 2016 Status changed from active, no longer recruiting to completed, According to an e-Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top